Webinar information
To watch the webinar, click here.
Genetic testing for patients affected with cardiomyopathy is recommended by multiple international expert groups. While its primary purpose has been to identify at-risk family members, the era of precision medicine is rapidly demonstrating how pinpointing the underlying genetic cause in affected individuals is of utmost importance for personalized management and therapies. This webinar will provide an overview of recent gene-specific recommendations, targeted therapies, and emerging clinical indications, highlighting how genetics is at the forefront of cardiomyopathy care.
Webinar objectives:
- Compare overlapping features of genetic and “acquired” cardiomyopathies, highlighting emerging clinical indications for genetic testing
- Describe recent advances in gene-specific therapies for patients with cardiomyopathy
- Examine how gene-specific recommendations in cardiomyopathy management guidelines highlight the importance of genetic testing for affected individuals
Speakers
Julie Hathaway
Julie Hathaway received her masters of science in Genetic Counseling from the University of Toronto. She is board certified in both the US and Canada. She was introduced to cardiac genetics early on in her career and this remains her main area of interest in the field. As a Clinical Liaison at Blueprint Genetics, Julie provides both internal and external clinical support and education. In addition, she contributes to research and creating scientific content. Prior to this, she worked as a clinical coordinator and cardiac genetic counselor and worked to establish the multidisciplinary BC Inherited Arrhythmia Program.